http://ift.tt/eA8V8J
BOSTON–(BUSINESS WIRE)–T1D Exchange, an organization dedicated to accelerating therapies and improving care in type 1 diabetes, today announced the organization has invested in Admetsys, the first company to develop an artificial pancreas technology for hospital and surgical care. The official collaboration with Admetsys is part of T1D Exchange’s multi-million-dollar initiative to support the development and delivery of automated insulin delivery technology and solutions. Terms of the financi
June 06, 2017 at 06:40PM
from
No comments:
Post a Comment